Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

ShangPharma Surges Most in 10 Months on Acquisition Offer

July 6 (Bloomberg) -- ShangPharma Corp., a Chinese medical researcher, surged the most in 10 months in New York after the company said it may be acquired at a premium to yesterday’s trading levels.

ShangPharma, based in Shanghai, climbed 18 percent to $8.09 at 1:28 p.m. in New York, the biggest advance since Aug. 12. Shares had lost 5.4 percent this year through yesterday.

ShangPharma received a non-binding proposal from Xin Hui and entities affiliated with him, to acquire all of the company’s outstanding American depositary receipts for $8.50 to $9.50 per share, according to a statement distributed by PRNewswire. Shares closed at $6.88 on July 5.

To contact the reporter on this story: Leon Lazaroff in New York

To contact the editor responsible for this story: Tal Barak Harif at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.